arrow
W

Wattana Sukeepaisarnjaroen

faculty of medicine khon kaen university
H指数:26
被引数:4,469

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of Standard Triple Therapy With or Without Statin in Helicobacter pylori Eradication: A Randomized Double‐Blind Placebo‐Controlled Trial

标准三联疗法联合或不联合他汀类药物根除幽门螺杆菌的疗效:一项随机双盲安慰剂对照试验

2026-10-130
OA
Overall Survival and Treatment Outcomes in Patients with Primary Biliary Cholangitis: A 10-Year Single-Center Retrospective Cohort Study

原发性胆汁性胆管炎患者总体生存率及治疗效果:一项10年单中心回顾性队列研究

2026-06-220
PRE
The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729–001): a phase 1a/b trial

小干扰RNA imdusiran作为单次和多次剂量在健康、随机和非随机慢性乙型肝炎受试者中的研究(AB-729–001):一项1a/1b期临床试验

2026-05-220
PRE
Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)

HIMALAYA研究中曲美木单抗联合度伐利尤单抗治疗不可切除肝细胞癌(肝癌)的五年总生存率更新报告

2026-05-100
OAAI
Effectiveness of silymarin with lifestyle intervention in NAFLD and metabolic syndrome: a prospective single-arm study

水飞蓟宾联合生活方式干预在非酒精性脂肪肝病和代谢综合征中的效果:一项前瞻性单臂研究

2026-04-080
PRE
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

HIMALAYA研究五-year总体生存率更新:曲美木单抗联合度伐利尤单抗治疗不可切除性HCC

2025-04-110
OAAI
The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand
2024-05-186
OA
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

tremelimumab联合durvalumab治疗不可切除肝细胞癌的III期喜马拉雅研究的四年总生存期更新

2024-05-0139
OA
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

卡博替尼联合阿特珠单抗与索拉非尼治疗晚期肝细胞癌 (COSMIC-312): 一项随机3期研究的最终结果

2024-04-0119
PRE
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma
2024-01-012
OA
Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma
2023-12-015
OAAI
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

喜马拉雅研究的简明语言摘要: tremelimumab和durvalumab治疗不可切除的肝细胞癌 (肝癌)

2023-09-0615
OA
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B
2022-10-0415
OAAI
Characteristics of Drug-induced Liver Injury in Chronic Liver Disease: Results from the Thai Association for the Study of the Liver (THASL) DILI Registry
2022-06-155
OAAI